Key result
Higher FIB-4 scores correlate with worse LVEF severity in decompensated heart failure.
Why the study?
Liver involvement is associated with heart failure progression, suggesting that liver biomarkers and scoring systems estimating liver fibrosis may have prognostic utility.
Observational (n=303)
No
Effect estimate: r = 0.344 to 0.506
p-value: p=<0.001
The FIB-4 score, a simple and inexpensive non-invasive liver fibrosis marker, correlates significantly with the severity of left ventricular ejection fraction reduction in patients with decompensated heart failure.
Does not support routine FIB-4 use in decompensated HF; leaves open its incremental prognostic value.
Background and Objectives: Heart failure is associated with high morbidity and mortality and linked with several pre-existing health conditions and risk factors. Early detection and prompt management in heart failure improves patient outcomes. Liver involvement is associated with heart failure disease progression, and hence liver biomarkers and liver fibrosis may have a prognostic impact. Several blood test based markers and scoring systems estimate liver fibrosis and hence can be useful prognostic tools. Materials and Methods: We retrospectively analyzed a series of 303 patients with decompensated heart failure in a city in western Romania over a period of 6 months. Several biochemical parameters were measured, the FIB-4 score was estimated and echocardiography was performed. Results for targeted variables are presented using descriptive statistics. Patients were analyzed based on their LVEF categories. Statistical analysis was based on ANOVA one-way tests for continuous variables and Chi-square tests for categorical variables. Pairwise comparisons were performed based on Bonferroni adjusted significance tests. The correlations between FIB-4 score, LVEF and NT-pro BNP in patients with and without diabetes and hypertension were explored using Spearman’s correlation coefficient. Result: Age, gender, NYHA class, death, history of (h/o) type 2 diabetes mellitus (T2DM), h/o coronary artery disease (CAD), h/o arrhythmias, sodium, potassium, creatinine, eGFR, uric acid, NT-pro BNP, left atrial volume, LDL, HDL, and TG were analyzed by LVEF categories using ANOVA one-way tests, Chi-square tests, and Bonferroni correction comparisons. We found a strong statistically significant correlation between each of NT-pro BNP, left atrial volume, LDL, and HDL with the LVEF categories. Discussion: Early detection of cardiac dysfunction leads to better management in patients with cardiovascular risk factors including diabetes and hypertension. High LDL and low HDL levels contribute to a reduction in left ventricular (LV) function. Available literature suggests the FIB-4 score as superior to other non-invasive markers of fibrosis. It utilizes the patient’s age, platelet count, AST, and ALT, which can be available retrospectively, making it an easy and inexpensive tool. FIB-4 score has a few limitations. Conclusions: Our study has shown a statistically significant positive correlation between severity categories of LVEF and FIB-4 score for heart failure patients with and without diabetes, and for heart failure patients with or without hypertension. We propose the implementation of FIB-4 score as a prognostic tool for heart failure.
No takes yet. Share an insight, caveat, or question.
Buzaș et al. (2024) conducted an observational in Decompensated heart failure (n=303). FIB-4 score was evaluated on Correlation between FIB-4 score and left ventricular ejection fraction (LVEF) (r = 0.344 to 0.506, p=<0.001). The FIB-4 liver biomarker score demonstrated a statistically significant positive correlation with the severity of left ventricular ejection fraction in patients with decompensated heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: